EGFR and non-small cell lung carcinoma: As shown in Table 1, a total of six large phase III trials showed a strong benefit of EGFR TKIs versus chemotherapy as a first-line treatment in terms of PFS and ORR in patients with EGFR-mutated NSCLC [13,14,15,16,17,18,19].